Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Change in Accured Expenses of $385000.0 for Q1 2026, up 185.56% year-over-year from $134824.9 in Q1 2025, and up 129.17% quarter-over-quarter from $168000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Change in Accured Expenses for 7 consecutive years, with $385000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 185.56% year-over-year to $385000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 312.24% YoY), while the FY2025 annual figure was $483000.0, up 1338.46% from the prior year.
- Change in Accured Expenses climbed to $385000.0 in Q1 2026 per VVOS's latest filing, from $168000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.1 million in Q2 2025 and bottomed at -$538000.0 in Q3 2022.
- Historically, Change in Accured Expenses has averaged $59647.1 across 5 years, with a median of $9000.0 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 4000.0% in 2024 and fell as far as 3855.56% in 2024.
- Vivos Therapeutics' Change in Accured Expenses stood at $788000.0 in 2022, then sank by 100.13% to -$1000.0 in 2023, then slumped by 3700.0% to -$38000.0 in 2024, then jumped by 542.11% to $168000.0 in 2025, then surged by 129.17% to $385000.0 in 2026.
- Business Quant data shows VVOS's Change in Accured Expenses at $385000.0 in Q1 2026, $168000.0 in Q4 2025, and -$331000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 298.00 Mn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 234.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 123.70 Mn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 112.90 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 19.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 43.01 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 4.80 Mn |
| 10 | Vivos Therapeutics | 4.96 Mn | 3.16 Mn | 2.95 Mn | 669,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 385,000.00 |
| Mar 31, 2026 | 385,000.00 |
| Dec 31, 2025 | 168,000.00 |
| Dec 31, 2025 | 168,000.00 |
| Sep 30, 2025 | -331,000.00 |
| Sep 30, 2025 | -331,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | -450,000.00 |
| Mar 31, 2025 | -450,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Sep 30, 2024 | 205,000.00 |
| Sep 30, 2024 | 205,000.00 |
| Jun 30, 2024 | -338,000.00 |
| Jun 30, 2024 | -338,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Mar 31, 2024 | 132,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |